Biotechnology

Immutep

Immutep released FY2026 Q2 earnings on February 24, 2026 (EST), with actual revenue of USD 2.017 M and EPS of USD -0.102

Immutep released FY2026 Q1 earnings on February 24 (EST), actual revenue USD 1.982 M, actual EPS USD -0.1003

Immutep released FY2026 Semi-Annual earnings on February 24 (EST), actual revenue USD 4.011 M (forecast USD 8.985 M), actual EPS USD -0.2029

Immutep Ltd. Announces Positive Phase II Trial Results for Eftilagimod Alfa in Soft Tissue Sarcoma

Immutep Ltd. Shows Progress in LAG-3 Immunotherapy

Analyst Storey Covers Healthcare Sector With Focus On Immutep Ltd

Immutep released FY2025 Q4 earnings on August 28 (EST), actual revenue USD 618.59 K, actual EPS USD -0.0873

Immutep released FY2025 9 Months Earnings on August 28 (EST), actual revenue USD 2.662M, actual EPS USD -0.1852

Immutep released FY2025 Q3 earnings on August 28 (EST), actual revenue USD 596.03K, actual EPS USD -0.0841

Immutep released FY2025 Annual Earnings on August 28 (EST), actual revenue USD 3.27 M (forecast USD 3.016 M), actual EPS USD -0.2735 (forecast USD -0.2392)

Immutep reports positive preliminary data for IMP761 phase 1 study

Immutep Ltd showcases immune system innovations at Jefferies Global Healthcare Conference

Immutep Ltd. Receives Polish Government Funding For EFTISARC-NEO Phase II Trial

Immutep reports significant efficacy results in lung cancer clinical trial

Immutep Ends Q3 With A Cash Balance of 92.5 Million Australian Dollars

Immutep Ltd Director Marc Voigt Acquires 2.4 Million Shares by Exercising Performance Rights

Immutep released FY2025 Q1 earnings on February 26 (EST), with actual revenue of 1.087 M USD and EPS of -0.0531 USD

Immutep released FY2025 Q2 earnings on February 26 (EST), actual revenue USD 979.06 K, actual EPS USD -0.0478

Immutep released FY2025 Semi-Annual Earnings on February 26 (EST), actual revenue 2.067 M USD (forecast 1.331 M USD), actual EPS -0.1011 USD (forecast -0.1416 USD)

Immutep released FY2024 9 Months Earnings on August 29 (EST), with actual revenue of 1.968 M USD and EPS of -0.1767 USD

PicoCELA

Agape ATP

Co-Diagnostics

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long QBTS Daily ETF

Netcapital

Akanda

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Liminatus Pharma

IMMP

Immutep is facing a securities class action after its ADRs plummeted 83% following the collapse of the TACTI-004 trial. The lawsuit targets CEO Marc Voigt and other executives for allegedly misleading investors about trial progress while withholding negative interim data. ADRs dropped from $2.76 to $0.48 on March 13, 2026. A court deadline for lead plaintiff appointment is set for July 6, 2026.

PUBT

Immutep Ltd

Immutep executives face securities class action after ADRs plunge 83% on trial collapse

Rosen Law Firm has announced a class action lawsuit for purchasers of Immutep Ltd. ADRs between March 24, 2025, and March 12, 2026. Investors may be entitled to compensation without upfront costs. The lawsuit claims that Immutep misled investors about the TACTI-004 trial's status, leading to damages when the truth emerged. Interested parties must move to serve as lead plaintiff by July 6, 2026.

prnewswire

19:55 ETIMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Pomerantz Law Firm has filed a class action lawsuit against Immutep Limited (NASDAQ: IMMP) for alleged securities fraud. Investors who suffered losses are encouraged to contact the firm by July 6, 2026, to be appointed as Lead Plaintiff. The lawsuit follows a significant drop in Immutep's stock price after the Independent Data Monitoring Committee recommended discontinuing a Phase III study due to futility. Pomerantz LLP specializes in corporate and securities class litigation, advocating for victims of corporate misconduct.

20:02 ETINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

Faruqi & Faruqi, LLP is investigating potential claims against Immutep Limited (NASDAQ: IMMP) and reminds investors of the July 6, 2026 deadline to seek lead plaintiff status in a federal securities class action. The complaint alleges that Immutep made misleading statements regarding the efficacy and safety of its TACTI-004 Phase III clinical trial, which was ultimately discontinued due to futility. Following this announcement, Immutep's ADR price fell by 82.6%. Investors who suffered losses are encouraged to contact the firm for legal options.

10:19 ETIMMP INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Rosen Law Firm is investigating potential securities claims for shareholders of Immutep Ltd. (NASDAQ: IMMP) due to allegations of misleading business information. Investors who purchased Immutep securities may be entitled to compensation through a class action lawsuit. Following a press release on March 13, 2026, regarding the discontinuation of a clinical trial, Immutep's ADR price fell by 82.6%. The firm encourages investors to choose qualified legal counsel for representation in securities class actions.

09:00 ETRosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Robbins LLP has announced a class action lawsuit on behalf of investors who purchased Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025, and March 12, 2026. The lawsuit alleges that Immutep misled investors about the efficacy of its drug candidate, TACTI-004, which was later recommended for discontinuation due to futility. Following this announcement, Immutep's stock price plummeted by approximately 83%. Shareholders interested in participating in the class action must submit their papers by July 6, 2026.

16:26 ETIMMP Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Immutep Limited

Rosen Law Firm is investigating potential securities claims for shareholders of Immutep Ltd. (NASDAQ: IMMP) due to allegations of misleading business information. Investors who purchased Immutep securities may be eligible for compensation through a class action lawsuit. Following a press release on March 13, 2026, regarding the discontinuation of a clinical trial, Immutep's ADR price fell 82.6%. The firm encourages investors to choose experienced legal counsel for representation in securities class actions.

14:54 ETRosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Rosen Law Firm is investigating potential securities claims for shareholders of Immutep Ltd. (NASDAQ: IMMP) due to allegations of misleading business information. Investors who purchased Immutep securities may be entitled to compensation through a class action lawsuit. Following a press release on March 13, 2026, regarding the discontinuation of a clinical trial, Immutep's ADR price fell 82.6%. The firm encourages investors to choose qualified legal counsel for representation in securities class actions.

20:17 ETRosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Immutep(IMMP.US)